A team of researchers at the Sant Pau Research Institute (IR Sant Pau) has demonstrated that the plasma biomarker p-tau217, obtained through a simple blood test, can predict the clinical progression of Alzheimer's disease even in its earliest stages, when symptoms are not yet evident. The study, published in the journal Neurology, reinforces the role of blood tests in the future of diagnosing and monitoring dementias.